Insider Selling: Monopar Therapeutics (NASDAQ:MNPR) Director Sells $206,012.66 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 2,891 shares of the business’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $71.26, for a total transaction of $206,012.66. Following the sale, the director owned 1,199 shares in the company, valued at $85,440.74. This trade represents a 70.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Performance

Shares of NASDAQ:MNPR opened at $71.42 on Friday. The firm has a 50 day moving average of $86.88 and a 200-day moving average of $77.39. Monopar Therapeutics Inc. has a 12 month low of $50.07 and a 12 month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. As a group, equities research analysts predict that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MNPR has been the topic of a number of research analyst reports. Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $109.00 to $119.00 in a report on Thursday, August 13th. Zacks Research downgraded shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Morgan Stanley restated an “overweight” rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research note on Monday, August 17th. Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Finally, HC Wainwright lifted their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Monopar Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $122.00.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Your Advocates Ltd. LLP purchased a new position in Monopar Therapeutics in the 1st quarter worth about $183,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Monopar Therapeutics in the 1st quarter valued at $250,000. Sei Investments Co. lifted its position in Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after acquiring an additional 656 shares during the last quarter. Bank of America Corp DE boosted its holdings in Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after acquiring an additional 53,336 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in Monopar Therapeutics in the 1st quarter worth about $3,458,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.